In a recently published study in the Diseases of the Colon & Rectum, a cohort of researchers executed a prospective, single-arm study to assess the safety and efficacy of RD2-Ver.02, an autologous whole blood product - in a flowable form - for the treatment of anal fistulas.
With a 69% rate of complete healing within 6 months, this innovative approach to perianal fistular disease treatment proved to be both safe and viable, achieving an acceptable healing rate for both cryptoglandular and Crohn's fistula in ano.
